Treat Cancer at Any Stage
A New Weapon in the War on Cancer: Kill Tumors and Activate a Systemic Immune Response
Treat locally, act globally. Intensity’s novel intratumoral delivery technology creates drug products that kill cancer cells in a manner that enables immune cells to enter and attack tumors throughout the body. Our vision is to meaningfully extend the lives of patients with metastatic cancer while maintaining their quality of life; for presurgical patients our mission is to avoid disease recurrence.
A New Weapon in the War on Cancer: Kill Tumors and Activate a Systemic Immune Response
Treat locally, act globally. Intensity’s novel intratumoral delivery technology creates drug products that kill cancer cells in a manner that enables immune cells to enter and attack tumors throughout the body. Our vision is to meaningfully extend the lives of patients with metastatic cancer while maintaining their quality of life; for presurgical patients our mission is to avoid disease recurrence.
Tumor
Injection
DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.
Diffusion
Through Tumor
Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.
Localized
Cell Death
The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.
System-wide
Immune Response
Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.
Increased
Survival
Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.
Technology and Clinical Data
Latest News
- Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
- Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Register for News Updates:
Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.